Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinoma

Kuo-Wei Huang, Pei-Chang Lee, Yee Chao, Chien-Wei Su, I-Cheng Lee, Keng-Hsien Lan, Chi-Jen Chu, Yi-Ping Hung, San-Chi Chen, Ming-Chih Hou and Yi-Hsiang Huang

Abstract

Background: The response rate to sorafenib is limited for unresectable hepatocellular carcinoma (HCC). Little is known about the long-term outcomes of objective responders. The role of second-line therapies on the survival of sorafenib-responders is unclear. We aimed to delineate the long-term outcomes and the role of subsequent treatment after responding to sorafenib.

Methods: From September 2012 to December 2019, 922 patients who received sorafenib treatment for unresectable HCC were retrospectively reviewed. Of these, 21 (2.3%) achieved a complete response (CR) and 54 (5.9%) had a partial response (PR) based on mRECIST criteria. Factors associated with survivals were analyzed.

Results: During the median follow-up of 35.3 months, the median duration of response was 18.3 months (range: 2.3–45.5) for patients achieving CR and 10.0 months (range: 1.9–60.3) for PR. The median overall survival (OS) was 39.5 months [95% confidence interval (CI): 28.4–50.5] including values not yet estimable for CR and 25.8 months for PR. Patients who experienced treatment-related adverse events (TRAEs) had better median OS than those without (44.9 versus 18.1 months, p = 0.003). Eventually, 53 patients developed tumor progression; 30 patients received second-line systemic treatment including nivolumab (n = 8), regorafenib (n = 15), and chemotherapy (n = 7). Sorafenib–nivolumab sequential therapy provided the best median OS versus sorafenib–regorafenib and sorafenib–chemotherapy in these patients (55.8, 39.5, and 25.5 months), respectively.

Conclusions: The response is durable for advanced HCC patients with CR or PR to sorafenib. Subsequent immunotherapy seems to provide the best survival. This information is important for characterizing outcomes of sorafenib-responders and the choice of sequential treatment.

Keywords: HCC, immunotherapy, regorafenib, sequential treatment, sorafenib

Introduction

Hepatocellular carcinoma (HCC) is the sixth most common cancer and the fourth leading cause of cancer-related death worldwide. HCC is most prevalent in East Asia and Africa, which are endemic areas of chronic viral hepatitis B and C. However, the incidence and mortality rates are rapidly rising in the United States and Europe in recent years imposing substantial health economic burdens. Despite the implementation of surveillance, hepatitis B vaccination, and hepatitis C direct-acting antiviral treatment, many patients still have unresectable and advanced-stage HCCs that require systemic therapy.

Sorafenib is a multikinase inhibitor and the first front-line systemic therapy approved for the treatment of unresectable HCC based on the results of two multicenter, randomized, phase III studies. However, the results are still limited for cases of...
objective tumor responses even after a long period of treatment experience (over 10 years). Previous studies and reports have presented sporadic HCC cases with complete response (CR) or partial response (PR) to sorafenib treatment. Nevertheless, there is little information on the duration of response and long-term outcomes of objective responders. In addition, several second-line treatments have been used for patients who failed sorafenib in recent years. The therapeutic efficacy and benefits of sequential systemic therapies for sorafenib objective responders are unclear. Here, we aimed to investigate the long-term outcomes of HCC patients who had objective tumor responses to sorafenib treatment and the factors associated with survival benefits in these patients.

Materials and methods

Populations
A total of 922 consecutive patients who received sorafenib treatment for unresectable HCC in Taipei Veterans General Hospital were retrospectively enrolled. The diagnosis of HCC was according to the criteria of American Association for the Study of Liver Diseases (AASLD) treatment guidelines for HCC. Among patients who had the following radiologic evaluation, 21 (2.3%) had a complete response (CR) and 54 (5.9%) had a partial response (PR) according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria and serum alpha-fetoprotein (AFP) levels. These 75 objective responders were evaluated for long-term treatment outcomes by sorafenib. In addition, the efficacy of post-sorafenib sequential systemic therapies was investigated in 30 patients who failed sorafenib treatment because of tumor progression. The algorithm of patient selection is shown in Figure 1. This study was approved by the Institutional Review Board (IRB), Taipei Veterans General Hospital (IRB number: 2014-03-009AC, 2019-10-001BC and 2021-04-006BC). The informed consent was waived by the IRB as a result of retrospective design and most enrolled patients died.

Intervention
According to the national health insurance criteria in Taiwan, sorafenib is reimbursed for HCC patients with Child-Pugh A liver function and extrahepatic metastasis or tumor invasion to major vessels, including the main portal vein and its first branch. Patients with HCC refractory to transarterial chemoembolization (TACE) (treatment failure after repeated TACE for at least three times within 12 months) and Child-Pugh A liver reserves have also been reimbursed for sorafenib since November 2016.
Sorafenib was initiated at 400 mg twice daily, and the dose was reduced or temporarily interrupted upon development of treatment-related adverse events (TRAEs) or hepatic deterioration. The option of second-line therapy after tumor progression was based on the Taiwan FDA-approved treatments, shared decision-making between the clinicians and patients, and the criteria of Taiwan National Health Insurance. During the study period, regorafenib was reimbursed for the patients with sorafenib-failed HCC in Child-Pugh A status. Besides, nivolumab was reimbursed during April 2019 to March 2020 with the same criteria for regorafenib. Regorafenib was administered orally 160 mg per day during the first 3 weeks of each 4-week cycle, and nivolumab was intravenously used at a dose of 2–3 mg/kg every 2 weeks. Fluorouracil-based or gemcitabine plus platinum-based chemotherapies were prescribed to eligible patients who did not meet the timing or criteria of reimbursed targeted agents after sorafenib failure. The dosage of second-line agents was adjusted according to the severity of TRAE and patients’ condition. Treatment was terminated with the occurrence of tumor progression, liver function deterioration, intolerable adverse events, or death.

Comparison
This retrospective study is designed to analyze the survival and clinical outcomes of sorafenib-responders. A comparison group was not defined in this study.

Outcomes
The long-term clinical outcomes and survival benefits were analyzed in objective responders to sorafenib treatment. Besides, the efficacy of post-sorafenib sequential systemic therapies was investigated in 30 patients who failed sorafenib treatment because of tumor progression. In addition, the most common TRAE of sorafenib, including hand–foot skin reaction (HFSR), diarrhea, and hypertension, were recorded and considered for survival analysis. Hand–foot skin reaction was characterized by erythema, dysesthesia, or paresthesia on the palms and soles together with rash. Diarrhea was characterized by an increase in frequency and loose or watery bowel movements, or both. The AE of hypertension was defined as new-onset of high blood pressure (>140/90 mmHg) in the cases without underline hypertension or more increased blood pressure that needs addition of medications in subjects with underlying hypertension. All TRAEs were documented and graded according to the Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0.

Time
The duration of patient collection was from September 2012 to December 2019, and the following data cutoff was on December 31, 2020.

Statistical analysis
Continuous variables were expressed as medians [interquartile ranges (IQR)] while categorical variables were analyzed as frequency and percentages. The Pearson chi-square analysis or Fisher’s exact test was used to compare categorical variables while the Mann–Whitney U test was applied for continuous variables. Overall survival (OS) and progression-free survival (PFS) from the beginning of sorafenib treatment to death or tumor progression, as well as post-sorafenib survival (PSS) from the time documented for sorafenib failure to death, were estimated via the Kaplan–Meier method and compared by a log-rank test. We also applied Prediction Of Survival in Advanced Sorafenib-treated HCC (PROSASH)-II score to differentiate OS of our patients. In addition, Cox’s proportional-hazard model was used to identify prognostic factors for survival. Schoenfeld residuals were used to test the assumption of proportional hazards (Supplemental Figure 1); \( p < 0.05 \) was considered statistically significant for all analyses. All statistical analyses were performed using the Statistical Package for Social Sciences (SPSS 26.0 for Windows, SPSS Inc, Chicago, IL, USA) and GraphPad Prism 8 (GraphPad Software, San Diego, CA, USA).

Results
Demographic characteristics of the patients
The entire cohort of sorafenib-treated HCC \( (n = 922) \) was male-predominant (78.9%) and most had chronic hepatitis B virus (HBV) infection (57.6%). Most patients were within Child-Pugh class A (86.1%); more than half of them were classified beyond albumin-bilirubin (ALBI) grade 1 (66.3%); 86.0% of tumors were at Barcelona Clinic Liver Cancer (BCLC) stage C; 57.9% with macroscopic vascular invasion, and
56.6% presented extrahepatic metastasis. The detailed baseline characteristics of the cohort are shown in Table 1.

Of the 75 objective responders (21 CR, 54 PR) to sorafenib treatment, three complete responders were at BCLC stage B and received sorafenib due to TACE failure. The maximal tumor size was smaller in CR patients (median size 2.5 versus 4.7 cm, \( p = 0.001 \)). The prevalence of macrovascular invasion or extrahepatic metastasis was comparable between CR and PR groups. Patients with complete tumor response had a longer treatment duration than patients with PR (751 versus 401 days, \( p = 0.001 \)); more patients with CR to sorafenib had experienced a dose reduction for more than 25% of the recommended dose (95.2% versus 70.4%, \( p = 0.021 \)). None of them received aspirin during sorafenib treatment. Detailed demographic characteristics and treatment conditions are shown in Table 2.

**Treatment outcomes of objective responders**

Of the 21 complete responders, the median time to response (TTR) and duration of response (DOR) were 4.3 and 18.3 months, respectively. The median TTR and DOR of PR patients were 2.8 and 10.0 months, respectively (Table 3). During the median follow-up period of 35.3 months (IQR, 16.6–46.3), five (6.7%) objective responders had ongoing sorafenib treatment at the data cutoff date. Eventually, 53 patients (70.6%) developed tumor progression and 43 patients died. The median PFS and OS were 18.8 (95% CI, 12.7–25.0) and 39.5 months (95% CI, 28.4–50.5), respectively. Figure 2(a) and (b) shows that patients with CR to sorafenib had a significantly longer PFS than those without AE (median OS: 44.9 versus 18.1, \( p = 0.003 \)). A significantly better OS was also observed in patients who developed diarrhea (median OS: 56.4 versus 30.5, \( p = 0.031 \)) or hypertension (median OS: 85.2 versus 35.3, \( p = 0.013 \)) during sorafenib treatment. No significant survival difference was noted according to the presence of HFSR [Figure 3(b)–(d)].

In addition, marginally longer PFS was observed in patients who developed TRAE than the others (median PFS: 21.0 versus 8.6 months, \( p = 0.064 \)). Patients who suffered from sorafenib-related diarrhea had significantly better PFS than the counterparts (median PFS: 18.8 versus 17.2 months, \( p = 0.048 \)). The benefits of HFSR or hypertension to PFS were marginal without statistical significance (Supplemental Figure 3). However, nearly all patients in this study had reduced sorafenib dose during the treatment course; no significant differences of PFS or OS was observed according to dose reduction (Supplemental Figure 4).

**Outcomes of sequential systemic therapies**

Of the 53 patients who discontinued sorafenib treatment because of tumor progression, 30 patients received sequential second-line systemic therapies including regorafenib \( (n = 15) \), nivolumab \( (n = 8) \), and chemotherapy \( (n = 7) \). Figure 4(a) and (b) shows that sequential nivolumab monotherapy provided significantly better PSS and OS versus chemotherapy. Comparable survival benefits were observed between nivolumab and regorafenib in patients with sorafenib-failed HCC (median PSS: not yet reached versus 15.5 months, \( p = 0.088 \); median OS: 55.8 versus 39.5 months, \( p = 0.064 \)). In multivariate analyses, nivolumab sequential therapy [hazard ratio (HR): 0.883, \( p = 0.030 \)] was independently associated with a better OS in sorafenib-failed HCC (Table 4).

**Discussion**

This is the largest real-world cohort of Asian patients with unresectable HCC treated by sorafenib to date; 8.2% of patients had an objective tumor response by radiological assessment. For advanced HCC patients with response to sorafenib, the duration of response could last for 1 year; the median OS was 39.5 months. Presence of TRAE, particularly diarrhea and hypertension, and administration of subsequent immunotherapy...
Table 1. Baseline characteristics of total HCC patients treated with sorafenib.

| Characteristics                                | Total |
|-------------------------------------------------|-------|
|                                                 | \( N = 922 \) |
| Age, years                                      | 65.2 ± 12.8 |
| Sex (male), \( n \) [%]                         | 727 (78.9) |
| Cause of disease, \( n \) [%]                   |       |
| Chronic hepatitis B                             | 531 (57.6) |
| Chronic hepatitis C                             | 217 (23.5) |
| BCLC stage B/C, \( n \) [%]                     | 129/793 (14.0/86.0) |
| Maximal tumor size, cm                          | 5.6 (3–10.3) |
| Infiltrative tumor type, \( n \) [%]             | 104 (11.3) |
| Macroscopic vascular invasion, \( n \) [%]       | 534 (57.9) |
| Main PVI (IVp4)                                 | 159 (17.2) |
| Extrahepatic metastasis, \( n \) [%]            | 522 (56.6) |
| Child-Pugh class A/B/C, \( n \) [%]             | 794/128/0 (86.1/13.9/0) |
| AFP (before Sorafenib), ng/mL                   | 377.37 (22.04–6349) |
| Prothrombin time, INR                           | 1.09 (1.04–1.16) |
| White blood cell, /cumm                         | 6000 (4600–8000) |
| Neutrophil-lymphocyte ratio                    | 3.50 (2.35–5.68) |
| Platelet count, K/cumm                          | 154 (103–222) |
| Creatinine, mg/dl                               | 0.88 (0.76–1.09) |
| ALT, U/L                                        | 39 (25–63) |
| AST, U/L                                        | 52 (34–94) |
| Albumin, g/dl                                   | 3.7 (3.4–4.1) |
| Total bilirubin, mg/dl                          | 0.88 [0.61–1.27] |
| ALBI grade 1/2/3, \( n \) [%]                   | 311/597/14 (33.7/64.8/1.5) |
| Sorafenib treatment                             |       |
| Dose, mg/day                                    | 640 (420–800) |
| Duration, days                                  | 67 (50–133) |
| Dose reduction, \( n \) [%]                     | 661 (71.7) |
| Dose reduction >25%, \( n \) [%]                | 422 (45.8) |
| Prior treatment to HCC, \( n \) [%]             |       |
| Surgical resection/ RFA, \( n \) [%]            | 248/248 (26.9/26.9) |
| TACE/ TACE failure (⩾3 times), \( n \) [%]      | 478/129 (51.8/14.0) |
| Number of prior treatment lines 0/1/2/>2, \( n \) [%] | 244/318/223/137 (26.5/34.5/24.2/14.8) |

AFP, alpha-fetoprotein; ALBI, albumin-bilirubin; AL(S)T, alanine(aspartate) aminotransferase; BCLC, Barcelona Clinic Liver Cancer; INR, international normalized ratio; PVI, portal vein invasion; RFA, radiofrequency ablation; TACE, transarterial chemoembolization. Continuous variables were expressed as median (interquartile).
Table 2. Basic characteristics of HCC patients with objective responses to sorafenib.

| Characteristics                                      | Total  | CR       | PR       | p value |
|------------------------------------------------------|--------|----------|----------|---------|
|                                                      | N=75   | n=21     | n=54     |         |
| Age, years                                           | 63.0 ± 11.7 | 59.6 ± 12.3 | 64.4 ± 11.6 | 0.501   |
| Sex (male), n (%)                                     | 62 [82.7] | 20 [95.2] | 42 [77.8] | 0.073   |
| Cause of disease, n (%)                               |        |          |          |         |
| Chronic hepatitis B                                   | 40 [53.3] | 11 [52.4] | 29 [53.7] | 0.918   |
| Chronic hepatitis C                                   | 24 [32.0] | 6 [28.6]  | 18 [33.3] | 0.691   |
| BCLC stage B/C, n (%)                                 | 3/72 [4.0/96.0] | 3/18 [14.3/85.7] | 0/54 [0/100.0] | 0.005   |
| Maximal tumor size, cm                                | 4.2 [0.6–21.7] | 2.5 [0.6–14] | 4.7 [1.3–21.7] | 0.001   |
| Infiltrative tumor type, n (%)                        | 6 [8.0] | 1 [4.8]  | 5 [9.3]  | 0.519   |
| Intrahepatic tumor number 1/2/≥3, n (%)              | 31/3/22 [41.3/4.0/29.3] | 12/0/3 [57.1/0/14.3] | 19/3/19 [35.2/5.6/35.2] | 0.151   |
| Macroscopic vascular invasion, n (%)                 | 41 [54.7] | 8 [38.1]  | 33 [61.1] | 0.072   |
| Main PVI (Vp4), n (%)                                 | 5 [6.7] | 1 [4.8]  | 4 [7.4]  | 0.680   |
| Extrahepatic metastasis, n (%)                       | 44 [58.7] | 10 [47.6] | 34 [63.0] | 0.226   |
| Child–Pugh class A/B/C, n (%)                         | 71/4/0 [94.7/5.3/0] | 19/2/0 [90.5/9.5/0] | 52/2/0 [96.3/3.7/0] | 0.405   |
| AFP (before Sorafenib), ng/mL                        | 133.5 [1.05–10,92,300] | 24.46 [1.05–4,27,773] | 287.08 [2.39–10,92,300] | 0.162   |
| Prothrombin time, INR                                 | 1.07 [0.9–1.34] | 1.05 [1.0–1.2] | 1.08 [0.9–1.34] | 0.710   |
| White blood cell, /cumm                               | 5500 [2300–13,400] | 5400 [2300–13,400] | 5600 [2400–11,900] | 0.944   |
| Neutrophil-lymphocyte ratio                          | 3.2 [0.48–21.5] | 2.46 [0.48–7.51] | 3.4 [1.06–21.5] | 0.105   |
| Platelet count, K/cumm                                | 143 [14–1118] | 171 [14–1118] | 137 [45–419] | 0.440   |
| Creatinine, mg/dl                                     | 0.87 [0.52–7.49] | 0.89 [0.71–7.49] | 0.85 [0.52–1.6] | 0.339   |
| ALT, U/L                                             | 41 [10–167] | 37 [18–167] | 42 [10–133] | 0.461   |
| AST, U/L                                             | 44 [12–168] | 39 [20–113] | 46 [12–168] | 0.415   |
| Albumin, g/dl                                        | 4.0 [2.7–4.9] | 3.9 [3.2–4.8] | 4 [2.7–4.9] | 0.972   |
| Total bilirubin, mg/dl                                | 0.89 [0.25–4.52] | 0.81 [0.44–4.52] | 0.91 [0.25–2.66] | 0.571   |
| ALBI grade 1/2/3, n (%)                               | 39/36/0 [52.0/48.0/0] | 11/10/0 [52.4/47.6/0] | 28/26/0 [51.9/48.1/0] | 0.967   |
| Sorafenib treatment                                   |        |          |          |         |
| Dose, mg/day                                         | 440 [100–800] | 380 [100–660] | 460 [160–800] | 0.064   |
| Duration, days                                       | 480 [121–1738] | 751 [288–1477] | 401 [121–1738] | 0.001   |
| Dose reduction, n (%)                                 | 72 [96.0] | 21 [100.0] | 51 [94.4] | 0.270   |
| Dose reduction >25%, n (%)                            | 58 [77.3] | 20 [95.2]  | 38 [70.4]  | 0.021   |
| Combination of LRT, n (%)                             | 37 [49.3] | 7 [33.3]  | 30 [55.6] | 0.084   |

(Continued)
Table 3. Clinical responses and outcomes of HCC with objective response to Sorafenib.

| Characteristics                               | Total          | CR            | PR            | p value |
|------------------------------------------------|----------------|---------------|---------------|---------|
|                                               | N=75           | n=21          | n=54          |         |
| TTR (months), median [range]                  | 3.3 [0.9–39.7] | 4.3 [0.9–28.5] | 2.8 [0.9–39.7]| 0.106   |
| DOR (months), median [range]                  | 12.1 [1.9–60.3]| 18.3 [2.3–45.5]| 10.0 [1.9–60.3]| 0.072   |
| PFS (months), median [95% CI]                 | 18.8 [12.7–25.0]| 29.3 [16.0–42.6]| 15.1 [11.1–19.1]| 0.011   |
| OS (months), median [95% CI]                  | 39.5 [28.4–50.5]| Not reached   | 25.8 [22.2–29.5]| <0.001  |
| Treatment-related adverse effect, n (%)       | 66 [88.0]      | 19 [90.5]     | 47 [87.0]     | 0.681   |
| Diarrhea, n (%)                               | 52 [69.3]      | 15 [71.4]     | 37 [68.5]     | 0.806   |
| Hypertension, n (%)                           | 32 [42.7]      | 10 [47.6]     | 22 [40.7]     | 0.589   |
| Persistent using sorafenib n (%)              | 5 [6.7]        | 4 [19.0]      | 1 [1.9]       | 0.007   |
| Progressive disease, n (%)                   | 53 [70.6]      | 14 [66.7]     | 39 [72.2]     | 0.635   |
| New extrahepatic metastasis, n (%)            | 20 [26.7]      | 5 [23.8]      | 15 [27.8]     | 0.366   |
| New intrahepatic metastasis, n (%)            | 32 [42.7]      | 12 [57.1]     | 20 [37.0]     | 0.410   |
| Intrahepatic growth, n (%)                    | 7 [9.3]        | 0 [0]         | 7 [13.0]      | 0.050   |
| Extrahepatic growth, n (%)                    | 8 [10.7]       | 0 [0]         | 8 [14.8]      | 0.034   |
| Major vascular progression, n (%)             | 2 [2.7]        | 0 [0]         | 2 [3.7]       | 0.315   |
| Death, n (%)                                  | 43 [57.3]      | 2 [9.5]       | 41 [75.9]     | <0.001  |

CI, confidence interval; CR, complete response; DOR, duration of response; HFSR, hand–foot skin reactions; PFS, progression-free survival; PR, partial response; OS, overall survival; TTR, time to response.
Figure 2. Survival benefits of HCC responders to sorafenib treatment according to tumor response: [a] progression-free survival (PFS) and [b] overall survival (OS) of HCC responders according to the tumor responses to sorafenib treatment. HCC, hepatocellular carcinoma.

Figure 3. Overall survival (OS) of HCC responders to sorafenib treatment according to the presence of treatment-related adverse events (TRAEs). OS according to the presence of [a] all TRAEs, [b] hand–foot skin reactions (HFSR), [c] diarrhea, and [d] hypertension. HCC, hepatocellular carcinoma.
were associated with better survival benefits in sorafenib-responders.

A low tumor response rate is the main disadvantage of sorafenib treatment for HCC. In the SHARP and Asian-Pacific study, only 2% and 3.3% of patients had partial response; no complete response was reported. According to an Italian multicenter study that enrolled 296 HCC patients, the overall objective response rate was 8%, including two patients (1%) with CR and 22 with PR (7%). In a Spanish multicenter retrospective study, 12 (1%) complete responders were identified from 1119 patients; the outstanding OS reached 85.8 months. Of the real-world cohorts in Taiwan, approximately 5–7% of HCC developed objective responses to sorafenib treatment. Similar to previous studies, the objective response rate of our cohort was low, but the therapeutic efficacy was durable in the sorafenib-responders.

According to clinical trials and real-world studies, the most common TRAEs of sorafenib included diarrhea, arterial hypertension, fatigue, and dermatological toxicities, mainly as HFSR. Previous studies suggested that the presence of adverse events may be of prognostic and predictive importance in sorafenib-treated HCC. Here, we found that the presence of diarrhea and hypertension were associated with better OS in the objective responders to sorafenib. Diarrhea was also associated with a better PFS. In contrast, no significant survival benefits of HFSR could be identified in these responders probably because most (69.3%) had expressed HFSR during sorafenib treatment. This finding confirms that optimal management of sorafenib-related AEs would prolong treatment duration and improve patients’ survival.

Dose reduction was often carried out in clinical practice in approximately 26–45% of patients, even the majority of AEs were grades 1–2. According to a previous study, sorafenib dose reduction can improve HCC survival and increase patients’ tolerance and adherence coupled with longer duration and a higher cumulative dose. In this study, most (96.0%) objective tumor responders had experienced a dose reduction, and 77.3% of them underwent a more than 25% dose reduction during sorafenib treatment. Dose reductions did not lead to survival differences probably because of the high application rate of this practice.

Aspirin use was reported in association with better clinical outcomes and survival benefits in patients who received sorafenib treatment for HCC. As to our patients, none of sorafenib-responders had used aspirin during the sorafenib or subsequent therapies for HCC. Therefore, we did not include aspirin use in the analysis. PROSASH-II score was suggested as the most-effective prognostic classification model for patients with sorafenib-treated HCC. However, no significant survival difference could be identified according to PROSASH-II model in our objective responders. It is possible that our patients were objective responders to sorafenib; consequently, PROSASH-II scores could not further differentiate them.
Table 4. Factors associated with overall survival in 30 HCC patients received sequential systemic therapy.

| Characteristics                      | Univariate analysis | Multivariate analysis |
|--------------------------------------|---------------------|-----------------------|
|                                      | HR  | 95% CI           | p          | HR  | 95% CI           | p          |
| Age, years                           |     |                  |           |     |                  |           |
| >60 versus ≤60                       | 1.083 | (0.361–3.247)     | 0.877     | NA  |                  |           |
| Sex                                  |     |                  |           |     |                  |           |
| Male versus Female                   | 0.999 | (0.221–4.516)     | 0.998     | NA  |                  |           |
| HBsAg-positive                       |     |                  |           |     |                  |           |
| Yes versus No                        | 2.143 | (0.713–6.440)     | 0.174     | 2.636 | (0.793–8.762) | NS         |
| Anti-HCV-positive                    |     |                  |           |     |                  |           |
| Yes versus No                        | 0.577 | (0.127–2.615)     | 0.476     | NA  |                  |           |
| Tumor size, cm                       |     |                  |           |     |                  |           |
| >5 versus ≤5                         | 0.813 | (0.275–2.402)     | 0.707     | NA  |                  |           |
| Tumor number                         |     |                  |           |     |                  |           |
| Multiple versus single               | 1.516 | (0.507–4.537)     | 0.457     | NA  |                  |           |
| Tumor shape                          |     |                  |           |     |                  |           |
| Infiltrative versus nodulear         | 1.623 | (0.357–7.384)     | 0.531     | NA  |                  |           |
| Macrovascular invasion                |     |                  |           |     |                  |           |
| Yes versus No                        | 2.494 | (0.775–8.022)     | 0.125     | 2.156 | (0.486–9.569) | NS         |
| Main PVI (Vp4)                       |     |                  |           |     |                  |           |
| Yes versus No                        | 0.647 | (0.081–5.155)     | 0.681     | NA  |                  |           |
| Extrahepatic metastasis              |     |                  |           |     |                  |           |
| Yes versus No                        | 0.510 | (0.170–1.532)     | 0.230     | NA  |                  |           |
| AFP, ng/ml                           |     |                  |           |     |                  |           |
| >400 versus ≤400                     | 1.474 | (0.505–4.305)     | 0.478     | NA  |                  |           |
| <10 versus ≥10                       | 1.260 | (0.345–4.606)     | 0.727     | NA  |                  |           |
| Prothrombin time, INR                |     |                  |           |     |                  |           |
| >1.2 versus ≤1.2                     | 1.158 | (0.374–3.119)     | 0.851     | NA  |                  |           |
| Platelet count                       |     |                  |           |     |                  |           |
| >100k versus ≤100k                   | 0.404 | (0.118–1.390)     | 0.151     | 0.467 | (0.089–2.434) | NS         |
| ALT, U/L                             |     |                  |           |     |                  |           |
| >40 versus ≤40                       | 0.948 | (0.311–2.888)     | 0.925     | NA  |                  |           |
| AST, U/L                             |     |                  |           |     |                  |           |
| >40 versus ≤40                       | 2.320 | (0.722–7.455)     | 0.158     | 1.247 | (0.278–5.599) | NS         |
| NLR                                  |     |                  |           |     |                  |           |
| >2.5 versus ≤2.5                     | 1.265 | (0.384–4.166)     | 0.699     | NA  |                  |           |
| ALBI grade                           |     |                  |           |     |                  |           |
| Grade 2, 3 versus 1                  | 0.913 | (0.286–2.913)     | 0.878     | NA  |                  |           |
| Sorafenib-AE                         |     |                  |           |     |                  |           |
| Yes versus No                        | 0.715 | (0.091–5.608)     | 0.750     | NA  |                  |           |
| Grade III AE                         |     |                  |           |     |                  |           |
| Yes versus No                        | 1.046 | (0.228–4.803)     | 0.954     | NA  |                  |           |
| Sequential therapy                   |     |                  |           |     |                  |           |
| Sorafenib–C/T                        | 1     | –                 | –         | 1    | –                 | –         |
| Sorafenib–Regorafenib                | 0.607 | (0.192–1.915)     | 0.394     | 0.434 | (0.125–1.504) | 0.188     |
| Sorafenib–Nivolumab                  | 0.112 | (0.013–0.970)     | 0.047     | 0.083 | (0.009–0.782) | 0.030     |

AEs, adverse events; AFP, alpha-fetoprotein; ALBI grade, albumin-bilirubin grade; AL[S]T, alanine(aspartate) aminotransferase; CI, confidence interval; C/T, chemotherapy; HBsAg, hepatitis B surface antigen; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HR, hazard ratio; INR, international normalized ratio; NLR, neutrophil-lymphocyte ratio; PVI, portal vein invasion.
Nivolumab and regorafenib have demonstrated their therapeutic effectiveness for the sorafenib-failed HCC according to the Checkmate-040 and RESCORCE trials in 2017. According to a Korean study, comparable efficacy and safety between nivolumab and regorafenib were observed in patients with sorafenib-failed advanced HCC. The median OS was 5.9 and 6.9 months for nivolumab and regorafenib, respectively. Nivolumab sequential therapy was independently associated with prolonged OS. Another retrospective study in Taiwan showed that subsequent nivolumab and regorafenib provided promising and comparable benefits to sorafenib-failed HCC. The OS was 14 and 11 months from the time of nivolumab and regorafenib commencement and 21.9 and 17.3 months in the nivolumab and regorafenib group since the beginning of sorafenib treatment. Here, subsequent nivolumab treatment provided an optimal PSS (not yet reached at data cutoff on December 31, 2020) that was better than the survival observed in the Asian cohort of Checkmate-040 trial (14.9 months). The median OS from initiation of sorafenib to death in patients who received sorafenib–nivolumab sequential therapy was up to 55.8 months. A comparable survival benefit attributed to subsequent regorafenib was also observed in our patients (median PSS: 15.5 months, median OS from sorafenib initiation: 39.5 months) similar to the results of RESCORCE trial (10.6 and 26.0 months, respectively). Real-world data of sorafenib–regorafenib showed median OS around 28.5 to 38.4 months. Our study focusing on responders to sorafenib, showed a median OS of 39.5 months by sorafenib–regorafenib sequencing. These data suggest that nivolumab and regorafenib have promising treatment efficacy and survival benefits as second-line therapies particularly in sorafenib-responders.

There are several limitations in this study. First, this is a retrospective study that only enrolled patients in single hospital. However, our hospital is the main leading tertiary medical center in Taiwan. The large case numbers and long-term follow-up period of this cohort as well as regular tumor reassessment and clinical evaluation ameliorates information bias as well. Second, the trough concentration of sorafenib was not checked in our patients, although it might predict the occurrence of serious AE, tumor response, and survival in patients with HCC. Third, most of our patients had chronic hepatitis B as the underlying hepatic disease. We should cautiously apply our experience to other populations. Finally, as a retrospective study, the genetic mutations of tumor, such as the specific BRAF alterations, and the tumor microenvironment, involving the pathophysiology of hypoxia-induced angiogenesis and immunosuppression, were not available. Precision and individualized approaches for systemic therapy of HCC are still in unmet need to select multikinase inhibitor-preferred or immune checkpoint inhibitor-preferred patients. Further clinical trials with precision and individualized approaches focusing on the genetics and microenvironment of tumor as well as the HCC etiology are needed to elucidate these issues.

In conclusion, although the objective response rate of HCC to sorafenib is low, the long-term benefit is durable. The presence of TRAE (particularly diarrhea and hypertension) was associated with better OS. Sequential therapy with nivolumab or regorafenib after sorafenib failure could provide promising and comparable benefits to HCC patients who had previous responses to sorafenib treatment. This information is important for characterizing outcomes of sorafenib-responders and the choice of sequential treatment.

**Ethics approval and consent to participate**

This study was approved by the Institutional Review Board (IRB), Taipei Veterans General Hospital (IRB number: 2014-03-009AC, 2019-10-001BC and 2021-04-006BC). The informed consent was waived by the IRB as a result of retrospective design and most enrolled patients died.

**Consent for publication**

The informed consent was waived by the IRB as a result of retrospective design.

**Author contribution(s)**

**Kuo-Wei Huang:** Data curation; Formal analysis; Methodology; Software; Writing – original draft.

**Pei-Chang Lee:** Data curation; Formal analysis; Methodology; Writing – original draft.

**Yee Chao:** Supervision.

**Chien-Wei Su:** Supervision; Validation.
I-Cheng Lee: Data curation.
Keng-Hsin Lan: Data curation.
Chi-Jen Chu: Data curation.
Yi-Ping Hung: Data curation.
San-Chi Chen: Data curation.
Ming-Chih Hou: Supervision.
Yi-Hsiang Huang: Conceptualization; Resources; Supervision; Validation; Writing – original draft; Writing – review & editing.

Acknowledgements
We thank the patients and their families/caregivers, the study investigators and their staff, and the Clinical Research Core Laboratory, Department of Medical Research, Taipei Veterans General Hospital.

Funding
This study is supported by grants from Taipei Veterans General hospital (V109C-048, V110C-144, and V111C-107).

Conflict of interest statement
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Availability of data and materials
The data that support the findings of this study are available from the corresponding author upon reasonable request.

Supplemental material
Supplemental material for this article is available online.

References
1. Villanueva A. Hepatocellular carcinoma. *N Engl J Med* 2019; 380: 1450–1462.
2. Singal AG, Lampertico P and Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: New trends. *J Hepatol* 2020; 72: 250–261.
3. McGlynn KA, Petrick JL and El-Serag HB. Epidemiology of hepatocellular carcinoma. *Hepatology* 2021; 73: 4–13.
4. Lee PC, Chen YT, Chao Y, et al. Validation of the albumin-bilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma. *Liver Int* 2018; 38: 321–330.
5. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med* 2008; 359: 378–390.
6. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. *Lancet Oncol* 2009; 10: 25–34.
7. Iavarone M, Cabibbo G, Piscaglia F, et al. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. *Hepatology* 2011; 54: 2055–2063.
8. Lee IC, Chen YT, Chao Y, et al. Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practice. *Medicine (Baltimore)* 2015; 94: e688.
9. Kim TS, Kim JH, Kim BH, et al. Complete response of advanced hepatocellular carcinoma to sorafenib: another case and a comprehensive review. *Clin Mol Hepatol* 2017; 23: 340–346.
10. Lin SM, Lu SN, Chen PT, et al. HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma. *Hepatol Int* 2017; 11: 199–208.
11. Rimola J, Diaz-González A, Darnell A, et al. Complete response under sorafenib in patients with hepatocellular carcinoma: relationship with dermatologic adverse events. *Hepatology* 2018; 67: 612–622.
12. Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* 2017; 389: 56–66.
13. El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. *Lancet* 2017; 389: 2492–2502.
14. Bruix J and Sherman M. Management of hepatocellular carcinoma: an update. *Hepatology* 2011; 53: 1020–1022.
15. Lencioni R and Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. *Semin Liver Dis* 2010; 30: 52–60.
16. Shao YY, Wang SY, Lin SM, et al. Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and
systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. *J Formos Med Assoc* 2021; 120: 1051–1060.

17. Lee PC, Chao Y, Chen MH, *et al.* Predictors of response and survival in immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. *Cancers (Basel)* 2020; 12: 182.

18. Qin S, Bai Y, Lim HY, *et al.* Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin *versus* doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. *J Clin Oncol* 2013; 31: 3501–3508.

19. Zaanan A, Williet N, Hebbar M, *et al.* Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study. *J Hepatol* 2013; 58: 81–88.

20. Robert C, Soria JC, Spatz A, *et al.* Cutaneous side-effects of kinase inhibitors and blocking antibodies. *Lancet Oncol* 2005; 6: 491–500.

21. Lee SW, Lee TY, Yang SS, *et al.* Sorafenib-related adverse events in predicting the early radiologic responses of hepatocellular carcinoma. *Gastroenterology* 2019; 12: 16–20.

22. Sansone V, Tovoli F, Casadei-Gardini A, *et al.* Comparison of prognostic scores in patients with hepatocellular carcinoma treated with sorafenib. *Clin Transl Gastroenterol* 2021; 12: e00286.

23. Lin TH, Shao YY, Chan SY, *et al.* High serum transforming growth factor-β1 levels predict outcome in hepatocellular carcinoma patients treated with sorafenib. *Clin Cancer Res* 2015; 21: 3678–3684.

24. Raoul JL, Kudo M, Finn RS, *et al.* Systemic therapy for intermediate and advanced hepatocellular carcinoma: sorafenib and beyond. *Cancer Treat Rev* 2018; 68: 16–24.

25. Lencioni R, Kudo M, Ye SL, *et al.* GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafineNib): second interim analysis. *Int J Clin Pract* 2014; 68: 609–617.

26. Hollebecque A, Cattan S, Romano O, *et al.* Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score. *Aliment Pharmacol Ther* 2011; 34: 1193–1201.

27. Granito A, Marinelli S, Negrini G, *et al.* Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib. *Therap Adv Gastroenterol* 2016; 9: 240–249.

28. Bettinger D, Schultheiss M, Knüppel E, *et al.* Diarrhea predicts a positive response to sorafenib in patients with advanced hepatocellular carcinoma. *Hepatology* 2012; 56: 789–790.

29. Koschny R, Gotthardt D, Koehler C, *et al.* Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma. *Oncology* 2013; 84: 6–13.

30. Estfan B, Byrne M and Kim R. Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy. *Am J Clin Oncol* 2013; 36: 319–324.

31. Akutsu N, Sasaki S, Takagi H, *et al.* Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy. *Int J Clin Oncol* 2015; 20: 105–110.

32. Otsuka T, Eguchi Y, Kawazoe S, *et al.* Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib. *Hepatol Res* 2012; 42: 879–886.

33. Cho JY, Paik YH, Lim HY, *et al.* Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma. *Liver Int* 2013; 33: 950–957.

34. Tovoli F, Ielasi L, Casadei-Gardini A, *et al.* Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients. *J Hepatol* 2019; 71: 1175–1183.

35. Tak KY, Nam HC, Choi JY, *et al.* Effectiveness of sorafenib dose modifications on treatment outcome of hepatocellular carcinoma: analysis in real-life settings. *Int J Cancer* 2020; 147: 1970–1978.

36. Ielasi L, Tovoli F, Tonmini M, *et al.* Beneficial prognostic effects of aspirin in patients receiving sorafenib for hepatocellular carcinoma: a tale of multiple confounders. *Cancers (Basel)* 2021; 13: 6376.

37. Lee CH, Lee YB, Kim MA, *et al.* Effectiveness of nivolumab *versus* regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment. *Clin Mol Hepatol* 2020; 26: 328–339.

38. Kuo YH, Yen YH, Chen YY, *et al.* Nivolumab *versus* regorafenib in patients with hepatocellular carcinoma after sorafenib failure. *Front Oncol* 2021; 11: 683341.

39. Yau T, Hsu C, Kim TY, *et al.* Nivolumab in advanced hepatocellular carcinoma: sorafenib-experienced Asian cohort analysis. *J Hepatol* 2019; 71: 543–552.

40. Finn RS, Merle P, Granito A, *et al.* Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the phase III RESORCE trial. *J Hepatol* 2018; 69: 353–358.
41. Yoo C, Byeon S, Bang Y, et al. Regorafenib in previously treated advanced hepatocellular carcinoma: impact of prior immunotherapy and adverse events. *Liver Int* 2020; 40: 2263–2271.

42. Granito A, Forgione A, Marinelli S, et al. Experience with regorafenib in the treatment of hepatocellular carcinoma. *Therap Adv Gastroenterol* 2021; 14: 1–19.

43. Noda S, Hira D, Osaki R, et al. Sorafenib exposure and its correlation with response and safety in advanced hepatocellular carcinoma: results from an observational retrospective study. *Cancer Chemother Pharmacol* 2020; 86: 129–139.

44. Gnoni A, Licchetta A, Memeo R, et al. Role of BRAF in hepatocellular carcinoma: a rationale for future targeted cancer therapies. *Medicina (Kaunas)* 2019; 55: 754.

45. Solimando AG, Summa S, Vacca A, et al. Cancer-associated angiogenesis: the endothelial cell as a checkpoint for immunological patrolling. *Cancers (Basel)* 2020; 12: 3380.